Positions and Employment
Hospital and Other Appointments
Education
Licensure
Board Certification
Post Doctorial Training
Academic Appointments
Awards
Trainees
Professional Societies
Commitee and/or Board Membership
Major Research Interests
Grant Reviewer
Journal Reviewer
Teaching Experience
Major Lectures and Visiting Professorships
Moderator in Major Conferences
Grant Support
Articles
Book Chapters
Manuscripts
Patents
Oral Presentations
Presentations in Japanese
POSITIONS AND EMPLOYMENT:
1988-1989 Junior resident, Osaka University Hospital, Osaka, Japan
1989-1992 Resident, National Osaka Minami Hospital, Osaka, Japan
1991-1992 Chief Resident of Gastroenterology, National Osaka Minami Hospital, Osaka, Japan
1992-1996 Research Fellow, Osaka University School of Medicine, Osaka, Japan
1996-1997 Senior Resident, Osaka University Hospital, Osaka, Japan
10/97-01/99 Deputy Chief Gastroenterologist, Kansai Rosai Hospital, Amagasaki, Japan
01/99-12/00 Postdoctoral Fellow, University of Alabama at Birmingham, Birmingham, AL
01/01-12/01 Research Instructor, Division of Human Gene Therapy, University of Alabama at Birmingham, Birmingham, AL
01/02- 09/05 Research Assistant Professor, Division of Human Gene Therapy, University of Alabama at Birmingham, Birmingham, AL
03/02-09/05 Associate Scientist, the Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, AL
10/03-09/05 Research Assistant Professor, Graduate Faculty of Department of Pathology, University of Alabama at Birmingham, Birmingham, AL
10/05-08/06 Research Associate Professor, Division of Human Gene Therapy, Department of Surgery, Medicine, and Pathology, University of Alabama at Birmingham, Birmingham, AL
10/05- 08/06 Research Associate Professor, Graduate Faculty of Department of Pathology, University of Alabama at Birmingham, Birmingham, AL
10/05-08/06 Scientist, the Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, AL
09/06- Associate Professor, Department of Surgery, University of Minnesota, Minneapolis, MN
Top of page
HOSPITALS AND OTHER APPOINTMENTS:
Osaka University Hospital (junior resident)
National Osaka Minami Hospital (resident)
Osaka University Hospital (senior resident)
Kansai Rosai Hospital (Deputy Chief Gastroenterologist)
Top of page
EDUCATION:
Osaka University School of Medicine M.D. 1988
Osaka University School of Medicine Ph.D. 1997
Top of page
LICENSURE:
License of Medical Doctor (JAPAN) 1988
License of Industrial Medical Care (JAPAN) 1999
Top of page
BOARD CERTIFICATION:
Board of Japanese Society of Gastroenterology 1999 (renewal pending)
Board of Japanese Society of Medicine 2005 (pending)
Top of page
POST DOCTORIAL TRAINING:
01/99-12/00 Post Doctorial Fellow Division of Human Gene Therapy, UAB
Top of page
ACADEMIC APPOINTMENTS:
1992-1996 Research Fellow Osaka University School of Medicine
01/01-12/01 Research Instructor University of Alabama at Birmingham, Department of Surgery, Division of Human Gene Therapy (Primary Appointment), Department of Medicine, Division of Human Gene Therapy (Secondary Appointment)
01/01-08/06 Associate Scientist University of Alabama at Birmingham Gene Therapy Center (Secondary Appointment)
01/02-09/05 Research Assistant Professor University of Alabama at Birmingham Department of Surgery, Division of Human Gene Therapy (Primary Appointment), Department of Medicine, Division of Human Gene Therapy (Secondary Appointment)
03/02-09/05 Associate Scientist, the Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama
10/03-09/05 Research Assistant Professor, Graduate Faculty of Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama
10/05-08/06 Research Associate Professor Division of Human Gene Therapy, Department of Surgery, Medicine, and Pathology, University of Alabama at Birmingham, Birmingham, Alabama
10/05-08/06 Research Associate Professor Graduate Faculty of Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama
10/05-08/06 Scientist the Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama
Top of page
AWARDS:
John R. Durant Award for Excellence in Cancer research 2001-Junior Faculty Category
University of Alabama at Birmingham Comprehensive Cancer Center
The Mary Crowley Medical Research Center (MCMRC) Excellence Award. At the 14th International Conference on Gene Therapy of Cancer, 2005. (MCMRC is a leading research hospital specializes in clinical translation of gene and cellular therapies for cancer patients, which is located within the Baylor University Medical Center in Dallas, TX.)
Top of page
TRAINEES:
Long P. Le (PhD curriculum of MD&PhD Program.), MY: Associate Mentor, 4/1/2002- 3/31/2005), He will start his medical residency in Brigham and Women’s Hospital this Summer.
Peter A. Nagi, MD. (T32 supported Research Fellow), MY: Mentor (7/1/2001-6/30/2002), Resident Research Award - Society for Surgery of the Alimentary Tract 2002, He will become a resident of UAB Department of Anestheology
Hidetaka A. Ono, MD, PhD. (Post-doctorial Fellow), MY: Mentor (7/1/2002-12/31/2004), Pedro J. Ramirez, MD. (T32 supported Research Fellow), MY: Mentor (7/1/2002-6/30/2004), After finishing clinical residency UAB, he joins GI Surgery team at Johns Hopkins University this Spring as a clinical fellow for further surgical training of pancreatic surgery.
Amy Nelson, BS.(Master Student of School of Natural Science UAB), MY: Mentor: (9/1/2005 - present)
Top of page
PROFESSIONAL SOCIETIES:
American Society of Gene Therapy
American Association for Cancer Research
American Gastroenterology Association
Japanese Society of Gene Therapy
Japanese Society of Cancer Research
Japanese Society of Medicine
Japanese Society of Gastroenterology
Japanese Society of Hepatology
Japanese Gastroenterological Endoscopy Society
Top of page
COMMITTEE AND/OR BOARD MEMBERSHIP:
American Society of Gene Therapy, Cancer Gene Therapy Committee Member (Nov 2004 - present)
Institutional Biosafety Committee Member (May 2005 - present)
Birmingham Japanese Supplementary School, Board Member (2003-2005)
Top of page
MAJOR RESEARCH INTERESTS:
Cancer gene therapy with Adenovirus Vector
Conditionally replicative adenovirus for the treatment of cancer
Non-invasive in vivo molecular imaging (optical and radionuclide-based)
Imaging-based monitoring during gene therapy and virotherapy
Transcriptional control of gene expression in the context of adenoviral vector
Adenoviral vector for higher fidelity control
Infectivity enhancement of adenoviral vectors
Gene therapy of gastrointestinal diseases
Gene therapy of pancreatic cancer
Gene therapy of esophageal cancer
Gene therapy of prostate cancer
Gene Therapy of breast cancer
Gene Therapy of multiple myeloma
Top of page
GRANT REVIEWER:
VA Merit
Dutch Cancer Society
Ireland Ministry of Health
The Israel Science Foundation
The British Academy for Cancer Research
Top of page
JOURNAL REVIEWER:
Gastroenterology
Cancer Research
Clinical Cancer Research
Molecular Cancer Therapeutics
Molecular Cancer Research
Gene Therapy
Cancer Gene Therapy
American Journal of Surgery
Journal of Endoclinology
Top of page
TEACHING EXPERIENCE:
1997-1999 Taught residents and nurses at Kansai Rosai Hospital (As Senior Physician)
01/00-12/02 Research Instructor, Division of Human Gene Therapy, Department of Surgery, Medicine and Pathology, University of Alabama at Birmingham
01/2002-08/06 Research Assistant Professor, Department of Surgery, Division of Human Gene Therapy University of Alabama at Birmingham
10/03-08/06 Research Assistant Professor, Graduate Faculty of Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama
Thesis Committee of Long P. Le (M.D., Ph.D. Student)
Thesis Committee of Amy Nelson (M.S. Student)
2005 Thesis Committee of Miho Murakami (Ph.D.. Student)
Top of page
MAJOR LECTURES AND VISITING PROFESSORSHIPS:
March 9, 2006 “Conditionally Replicative Adenovirus for GI Cancers” UAB-Comprehensive Cancer Center, Experimental Therapeutics Seminar Series.
July 28, 2005 “Improving Adenovirus-Based Virotherapy Agents” Invited Lecture at Japanese Society of Gene Therapy
July 25, 2005 “Evolving Adenovirus-Based Virotherapy Agents” Senimar at Saitama Medical Collage.
July 15, 2005 “Evolving Adenovirus-Based Virotherapy Agents” Senimar at Kyushu University.
July 25, 2005 “Evolving Adenovirus-Based Virotherapy Agents” Senimar at National Institute of Biomedical Innovation.
July 4, 2005 “Evolving Adenovirus-Based Virotherapy Agents” Senimar at Tohoku University.
April 21, 2005 “Evolving Adenovirus-Based Virotherapy Agents” at UCLA
July 14, 2004 “Development of New Generation Conditionally Replicative Adenovirus (CRAds) for Gastrointestinal Cancers” University of Pennsylvania, Division of Gastroenterology.
May 20, 2004 “Development of New Generation Conditionally Replicative Adenovirus (CRAds) for Gastrointestinal Cancers” Tulane University, Division of Hematology Oncology.
January 30, 2004 Gene Therapy Symposium, title: “Next Generation CRAd for GI cancer Gene Therapy “, co-sponsered by Kinki Bio-Industry Development of Japan and Kansai Bureau, Ministry of Economy, Trade and Industry of Japanese Government. (invited speaker)
January 6, 2004 Gene Therapy Seminar Series: “Development of New Generation Conditionally Replicative Adenovirus (CRAds) for Gastrointestinal Cancers”
December 15, 2003 “CRAd for GI cancer Gene Therapy”, Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan. (invitation)
December 12, 2003 “CRAd for GI cancer Gene Therapy”, Kyoto University, Kyoto, Japan. (invitation)
December 11, 2003 Symposium: Virology and Its Gene Therapy Application: “Next Generation CRAd for GI cancer Gene Therapy”, The 26th Annual Meeting, The Molecular Biology Society of Japan, Kobe Japan. (invited symposist)
December 9, 2003 “CRAd for GI cancer Gene Therapy”, RIKEN Institute, Tsukuba Japan. (invitation)
July 22, 2003 “Development of New Generation CRAds for GI cancer Gene Therapy”, Osaka Univ. Div. of Health Science, Osaka Japan. (invitation)
July 18, 2003 “Development of New Generation CRAds for GI cancer Gene Therapy”, Juntendo University , Department of Gastroenterology, Tokyo Japan. (invitation)
July 17, 2003 “Development of New Generation CRAds for GI cancer Gene Therapy”, National Cancer Center Research Institute, Tokyo Japan. (invitation)
July 15, 2003 “Development of New Generation CRAds for GI cancer Gene Therapy”, Department of Gene Therapy Science, Osaka University, Osaka Japan. (invitation)
March 17, 2003 PAT 708: PRINCIPLES OF GENE THERAPY “Replicative Viruses for Cancer Therapy“, University of Alabama at Birmingham
December 14, 2002 Cancer of the Esophagus and Gastric Cardia: From Gene to Cure, Immunotherapy, Gene therapy, “Possibilities for gene therapy”, Amsterdam, the Netherlands
April 3, 2002 PAT 708: PRINCIPLES OF GENE THERAPY “Regulation of Gene Expression (or transcriptional targeting)“, University of Alabama at Birmingham
October 8, 2001 The State-of-Art Introduction for Gene Therapy of Gastrointestinal Cancers The 9th United European Gastroenterology Week 2001 at Amsterdam, the Netherlands
October 10, 2001 “Characterization of the cyclooxygenase-2 (cox-2) promoter in adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers” Free University of Amsterdam, the Netherlands
October 11, 2001 “Characterization of the cyclooxygenase-2 (cox-2) promoter in adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers” Academic Medical Center at Amsterdam, the Netherlands
October 12, 2001 “Characterization of the cyclooxygenase-2 (cox-2) promoter in adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers” University Center of Pharmacy, University of Groningen, Groniongen, the Netherlands
April 7, 2001 “Utility of Cox-2 Promoter for Systemic Cancer Targeting" CapCURE Gene Therapy Summit Meeting at Baltimore
Nov. 1997 “Anti-viral Effect of Single Chain Antibody against Hepatitis B Virus Core Antigen” Gene Therapy Seminar Series at Gene Therapy Center at University of Alabama at Birmingham
Nov. 1994 “Liver Specific Expression of Hepatitis C virus Core Antigen Using Asialoglycoprotein Receptor Mediated Gene Delivery” Gene Therapy Seminar Series at Gene Therapy Program at University of Alabama at Birmingham
June 6, 1992 “Diagnosis and Treatment of Hepatitis C” Lecture at Doctors Association of Kawachinagano
Top of page
MODERATOR IN MAJOR CONFERENCES:
American Society for Cancer Research (AACR), the 97th Annual Meeting, April 2006, Washington DC, Co-Chair, Mini symposium “Gene and Vector Based Therapies”
Cold Spring Harbor Meeting, Target Definition & Vector Design for Molecular Medicine, Nov 2005, Session Chair.
Cold Spring Harbor Meeting, Vector Targeting for Gene Therapy, Mar 2003, Session Chair
United European Gastroenterology Week (UEGW), the 9th Annual Meeting , Amsterdam, 2001, Session Co-chair, “Gene Therapy”
Top of page
GRANT SUPPORT:
Federal (Active)
NIH/NIDDK (R01 DK63615, PI: Yamamoto) 07/01/03-6/30/08
Role: PI
Enhanced CRAd for Esophageal Adenocarcinoma
The goal is to develop a clinically feasible conditionally replicative adenovirus by applying infectivity enhancement and promoter based control for esophageal adenocarcinioma.
NIH/NCI (P20CA101955, PI: Vickers.) 01/01/2006-12/31/2007
Role: Project Leader of Pilot Project #4
Development of New Generation CRAd for Pancreatic Cancer
To develop a new generation CRAd with non-invasive imaging capability for CRAd replication monitoring
NIH/NCI (R01 CA94084, PI: Curiel) 03/01/02-2/28/07
Role: Co-PI
Pancreatic carcinoma specific replicative adenoviral agent
The goal is to develop a clinically feasible conditionally replicative adenovirus by applying infectivity enhancement and promoter based control.
Federal (Pending)
NIH/NCI (R01 CA94084, Competing Continuation, PI: Yamamoto) 03/01/07-2/28/12
Role: Co-PI
Pancreatic carcinoma specific replicative adenoviral agent
The goal is to develop a clinically feasible conditionally replicative adenovirus by applying infectivity enhancement and promoter based control.
DOD PCRP(Yamamoto) 01/01/07-12/31/10
Role: Co-PI
Development of Novel Biological Imaging Modality for Prostate Cancer Based on Replicative Adenovirus System
Development of prostate cancer detection modality based on replication competent adenoviral technology.
NIH (R01 Fujihashi) 01/01/07-12/31/12
(PI: Fujihashi, Co-I: Yamamoto)
NALT-BASED ADJUVANTS FOR MUCOSAL IMMUNITY IN AGING
Determine the age-associated immunological changes of T and B cell function in Nasopharyngeal-associated lymphoreticular tissues (NALT).
NIH (R01 Fujihashi) 01/01/07-12/31/12
(PI: Fujihashi, Co-I: Yamamoto)
Flt3 Ligand Targets NALT DCs for Salivary IgA Responses
By targeting NALT with FL-based adjuvants, we preferentially induce direct migration of NALT DCs to the SMG and enhance the induction of mucosal S-IgA Ab responses. We also assess if FL-based immune modulator induced DCs are also interact with T cells and salivary B cells for the induction of Ag-specific S-IgA Ab responses in the SMGs.
Past grant support
DOD (DAMD17-03-1-0104, Yamamoto) 02/01/2003-01/31/2006 (Principal Investigator: Yamamoto)
Cyclooxygenase-2 Promoter-Based, Infectivity-Enhanced, Conditionally Replicative Adenovirus for Prostate Cancer
P50 CA89019 (Bland) 09/30/00-09/30/05
NIH/NCI P #4 (PI: Curiel, Co-I: Yamamoto)
Gene therapy specifically directed at tumor vasculature
NORD Research Grant Program
04/01/02-03/31/03, P.I.: Yamamoto
Novel Gene Therapy Approach for Multiple Myeloma Using Infectivity Enhanced Adenovirus Vector Expressing STAT-induced STAT inhibotor-1 (SSI-1)
AVON Breast Cancer Research and Care Program
01/01/02-12/31/02, P.I.: Yamamoto
Conditionally Replicative Adenovirus for Breast Cancer
Lustgarten Foundation (Curiel)
01/01/02-12/31/02, P.I.: Curiel, Co-Investigator: Yamamoto
Pancreatic carcinoma specific replicative adenoviral agent
DOD (PC010541, Buchsbaum)
12/01/2001-11/31/2004, PI: Buchsbaum, Co-Investigator: Yamamoto
Genetic Radiotherapy of Prostate Cancer
Top of page
ARTICLES:
1. Le LP, Le HN, Nelson AR, Matthews DA, Yamamoto M, Curiel DT. Core Labeling of Adenovirus with EGFP. Virology (in press)
2. Bauerschmitz GJ, Kanerva A, Yamamoto M, Nettelbeck DM, Hakkarainen T, Dall P, Curiel DT, Hemminki A. Triple targeted oncolytic adenoviruses featuring the Cox2 promoter, E1A trans-complementation and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther (in press)
3. Le LP, Le HN, Dmitriev IP, Davydova JG, Gavrikova T, Yamamoto S, Curiel DT, Yamamoto M. Dynamic Monitoring of Oncolytic Adenovirus In Vivo by Genetic Capsid Labeling. J Natl Cancer Inst. 2006 Feb 1;98(3):203-14.
4. Ono HA, Le LP, Davydova JG, Gavrikova T, Yamamoto M. Non-invasive Visualization of Adenovirus Replication with a Fluorescent Reporter in the E3 Region. Cancer Res. 2005 Nov 15;65(22):10154-8.
5. Stoff-Khalili MA, Stoff A, Rivera AA, Mathis JM, Everts M, Wang M, Kawakami Y, Waehler R, Mathews QL, Yamamoto M, Rocconi RP, Siegal GP, Richter DF, Dall P, Zhu ZB, Curiel DT. Gene Transfer to Carcinoma of the Breast with Fiber-Modified Adenoviral Vectors in a Tissue Slice Model System. Cancer Biol Ther. 2005 Nov 8;4(11)
6. Masato Yamamoto, Norihiro Nishimoto, Julia Davydova, Tadamitsu Kishimoto and David T. Curiel. Suppressor of Cytokine Signaling-1 (SOCS-1) Expression by Infectivity Enhanced Adenoviral Vector Inhibits IL-6 Dependent Proliferation of Multiple Myeloma Cells. Cancer Gene Therapy 2005 Aug 5; [Epub ahead of print].
7. Masato Yamamoto and David T. Curiel. Cancer Gene Therapy. Technology in Cancer Research and Treatment 2005 Aug;4(4):315-30.
8. Gommans WM, van Eert SJ, McLaughlin PMJ, Harmsen MC, Yamamoto M, Curiel DT, Haisma HJ, Rots MG. The carcinoma-specific Epithelial Glycoprotein-2 promoter controls efficient and selective gene expression in an adenoviral context. Cancer Gene Therapy 2005 Aug 12; [Epub ahead of print]
9. Lu B, Makhija SK, Nettelbeck DM, Rivera AA, Wang M, Komarova S, Zhou F, Yamamoto M, Haisma HJ, Alvarez RD, Curiel DT, Zhu ZB. Evaluation of tumor-specific promoter activities in melanoma. Gene Ther. 2005 Feb;12(4):330-8.
10. Huang CM, Shi ZK, DeSilva TS, Yamamoto M, Van Kampen KR, Elmets CA, Tang DC. A Differential Proteome in Tumors Suppressed by an Adenovirus-based Skin Patch Vaccine Encoding Human Carcinoembryonic Antigen. Proteomics 2005 Mar;5(4):1013-23.
11. Tekant Y, Davydova J, Ramirez PJ, Curiel DT, Vickers SM, Yamamoto M. Oncolytic adenoviral therapy in gallbladder carcinoma. SURGERY 2005 May:137(5):527-35.
12. Kirby TO, Rivera A, Rein D, Wang M, Ulasov I, Breidenbach M, Kataram M, Contreras JL, Krumdieck C, Yamamoto M, Rots MG, Haisma HJ, Alvarez RD, Mahasreshti PJ, Curiel DT. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res. 2004 Dec 15;10(24):8697-703.
13. Rein DT, Breidenbach M, Kirby TO, Han T, Siegal GP, Bauerschmitz GJ, Wang M, Nettelbeck DM, Tsuruta Y, Yamamoto M, Dall P, Hemminki A, Curiel DT. A Fiber-Modified, Secretory Leukoprotease Inhibitor Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer. Clin Cancer Res. 2005 Feb 1;11(3):1327-1335.
14. Liang Q, Yamamoto M, Curiel DT, Herschman HR. Noninvasive imaging of transcriptionally restricted transgene expression following intratumoral injection of an adenovirus in which the COX-2 promoter drives a reporter gene. Mol Imaging Biol. 2004 Nov-Dec;6(6):395-404.
15. Ono HA, Davydova JG, Adachi Y, Takayama K, Barker SD, Reynolds PN, Krasnykh VN, Kunisaki C, Shimada H, Curiel DT, Yamamoto M. Promoter-Controlled Infectivity Enhanced Conditionally Replicative Adenoviral Vectors for the Treatment of Gastric Cancer. J Gastroenterol. 2005 Jan;40(1):31-42.
16. Rein DT, Breidenbach M, Nettelbeck DM, Kawakami Y, Siegal GP, Huh WK, Wang M, Hemminki A, Bauerschmitz GJ, Yamamoto M, Adachi Y, Takayama K, Dall P, Curiel DT. Evaluation of tissue-specific promoters in carcinomas of the cervix uteri. J Gene Med. 2004 Nov; 6(11) 1281–1289.
17. Buchsbaum DJ, Cahudhuri TR, Yamamoto M and Zinn KR. Gene expression imaging with radiolabeled peptides. Annals of Nuclear Medicine 2004; 18(4): 275–283.
18. Masato Yamamoto. Conditionally Replicative Adenovirus for Gastrointestinal Cancers. Expert Opinion on Biological Therapy. 2004 Aug;4(8):1241-50.
19. Rivera AA, Davydova J, Schierer S, Wang M, Krasnykh V, Yamamoto M, Curiel DT, Nettelbeck DM. Combining High Selectivity of Replication with Fiber Chimerism for Effective Adenoviral Oncolysis of CAR-Negative Melanoma Cells. Gene Therapy, 2004 Dec 1; 11(23)1694 - 1702.
20. Davydova J, Le LP, Gavrokova T, Wang M, Krasnykh V, Yamamoto M. Infectivity-enhanced Cyclooxygenase-2-based Conditionally Replicative Adenoviruses for Esophageal Adenocarcinoma. Cancer Research. 2004 Jul 15:64(12):4319-27.
21. Le LP, Everts M, Dmitriev IP, Davydova JG, Yamamoto M, Curiel DT. Fluorescently Labeled Adenovirus with pIX-EGFP for Vector Detection. Molecular Imaging, 2004 Apr;3(2):105-16.
22. Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA 3rd, Yamamoto M, Alvarez RD, Curiel DT. Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter. Gene Ther. 2004 Apr;11(7):645-8. (My name miss-spelled as Yamaoto, erratum submitted)
23. Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, Barker S, Yamamoto M, Li F, Alvarez RD, Curiel DT. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther. 2004 Apr;11(4):256-62. (My name miss-spelled as Yamaoto, erratum submitted)
24. Lam JT, Kenerva A, Bauerschmitz GJ, Takayama K, Suzuki K, Yamamoto M, Bhoola SM, Wang M, Barnes MN, Alvarez RD, Siegal GP, Curiel DT and Hemminki A. Evaluation of Five Replicative adenoviruses for Ovarian Cancer Therapy. Journal of Gene Medicine. 2004 Oct;6(12)1333-1342.
25. F Yamamoto M, Curiel DT. Nonreplicating DNA viral vectors for suicide gene therapy: the adenoviral vectors. Methods Mol Med. 2004;90:61-70.
26. Kanerva A, Bauerschmitz GJ, Yamamoto M, Lam JT, Alvarez RD, Siegal GP, Curiel DT, Hemminki A. A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther. 2004 Mar;11(6):552-9.
27. Buskens CJ, Marsman WA, Wesseling JG, Offerhaus GJ, Yamamoto M, Curiel DT, Bosma PJ, van Lanschot JJ. A genetically retargeted adenoviral vector enhances viral transduction in esophageal carcinoma cell lines and primary cultured esophageal resection specimens. Ann Surg. 2003 Dec;238(6):815-24.
28. Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, Vickers SM and Curiel DT. Infectivity Enhanced, Cyclooxygenase-2 Promoter-Based Conditionally Replicative Adenovirus for Pancreatic Cancer. Gastroenterology. 2003 October; 125(4):1203-1218
29. Nettelbeck DM, Rivera AA, Davydova J, Dieckmann D, Yamamoto M, Curiel DT. Cyclooxygenase-2 promoter for tumour-specific targeting of adenoviral vectors to melanoma. Melanoma Res. 2003 Jun;13(3):287-292
30. Yamamoto M, Davydova J, Takayama K, Alemany R and Curiel DT. Transcription Initiation Activity of Adenoviral Left End Sequence in E1 Deleted Adenoviral Vectors. Journal of Virology. 2003 Jan 77(2):1633–1637
31. Nagi P, Vickers S, Davydova J, Barker S, Adachi Y, Takayama K, Krasnykh V, Curiel DT and Yamamoto M. Development of a Therapeutic Adenoviral Vector for Cholangiocarcinoma Combining Infectivity-Enhancement and Tumor-Restricted Gene Expression. Journal of Gastrointestinal Surgery, 7(3):364-371.
32. Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, Curiel DT, Hemminki A. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J Gene Med. 2003 Apr;5(4):300-10,
33. Suzuki K, Alemany R, Yamamoto M, Curiel DT. The presence of the adenoviral E3 gene improves the oncolytic potency of conditionally replicative adenoviruses. Clinical Cancer Research. 2002 Nov;8(11):3348-59.
34. Wesseling JG, Yamamoto M, Adachi Y, Bosma PJ, van Wijland M, Blackwell JL, Li H, Reynolds PN, Dmitriev I, Vickers SM, Huibregtse K and Curiel DT. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Ther. 2001 Dec;8(12):990-6.
35. Adachi Y, Reynolds PN, Yamamoto M, Minghui W, Takayama K, Matsubara S, Muramatsu T and Curiel DT. A Midkine promoter-based conditionally replicative adenovirus for the treatment of of pediatric solid tumors and bone marrow tumor purging. Cancer Research. 2001 Nov 1:61(21):7882-7888.
36. Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT. Characterization of the Cyclooxygenase-2 Promoter in an Adenoviral Vector and Its Application for the Mitigation of Toxicity in Suicide Gene Therapy of Gastrointestinal Cancers. Molecular Therapy 2001 Mar;3(3):385-94.
37. Casado E, Gomez-Navarro J, Yamamoto M, Adachi Y, Arafat W, Barker SB, Wang M, Mahasreshti P, Gonzalez Baron M, Pustilnik T, Siegal G, Alvarez R, Curiel DT. Strategies To Accomplish Targeted Expression Of Transgenes In Ovarian Cancer For Molecular Therapeutic Applications. Clinical Cancer Research. Clin Cancer Res. 2001 Aug;7(8):2496-504.
38. Adachi Y, Reynolds PN, Yamamoto M, Grizzle WE, Overturf K, Matsubara S, Muramatsu T, Curiel DT. Midkine promoter-bated adenoviral vector gene delivery for pediatric solid tumors. Cancer Res. 2000 Aug 15;60(16):4305-10
39. Yamamoto M, Hayashi N, Takehara T, Ueda K, Mita E, Tatsumi T, Sasaki Y, Kasahara A, Hori M. Intracellular single-chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells. Hepatology 1999 Jul;30(1):300-7
40. Yamamoto M, Hayashi N, Miyamoto Y, Takehara T, Mita E, Seki M, Fusamoto H, Kamada T. In vivo transfection of hepatitis C virus complementary DNA into rodent liver by asialoglycoprotein receptor mediated gene delivery. Hepatology 1995 Sep;22(3):847-55
41. Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito Y, Sasaki Y, Yamaguchi Y, Nakase H, Noda K, Enomoto N, Arai K, Yamada Y, Yoshihara H, Tujimura T, Kawano K, Yoshikawa K, Kamada T. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Research 1996 Jul 1;56(13):3004-9
42. Tatsumi T, Takehara T, Katayama K, Mochizuki K, Yamamoto M, Kanto T, Sasaki Y, Kasahara A, Hayashi N. Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepatology 1997 May;25(5):1108-14
43. Takehara T, Hayashi N, Yamamoto M, Miyamoto Y, Fusamoto H, Kamada T. In vivo gene transfer and expression in rat stomach by submucosal injection of plasmid DNA. Human Gene Therapy 1996 Mar 20;7(5):589-93
44. Yamamoto M, Hayashi N, Miyamoto Y, Kamada T. HCV gene transfected animal using receptor mediated gene delivery. Nippon Rinsho 1995 Sep;53 Suppl:107-11
45. Takehara T, Hayashi N, Miyamoto Y, Yamamoto M, Mita E, Fusamoto H, Kamada T. Expression of the hepatitis C virus genome in rat liver after cationic liposome-mediated in vivo gene transfer. Hepatology 1995 Mar;21(3):746-51
46. Masato Yamamoto, Masayoshi Horimoto, Eiji Mita, Haruya Meren, Hideyuki Fusamoto and Tomozumi Kuroda. A case of rupture of mesenteric vein due to idiopathic portal hypertension with arterio-portal fistula. (Japanese) Proceeding of Abdominal Emergency Medicine 1989 9(4):647-650.
Top of page
BOOK CHAPTERS:
Masato Yamamoto, David T. Curiel. Gene Therapy of Pancreatic Cancer- PANCREATIC CANCER Editors: Daniel D. Von Hoff, Douglas B. Evans, Ralph H. Hruban. Jones and Bartlett Publishers. 2005 ISBN: 0-7637-2178-6
Top of page
MANUSCRIPTS:
Major Manuscripts in Submission
1. Ramírez PJ, Ono HO, Davydova J, Krasnykh V, Takayama K, Timme TL, Curiel DT, Vickers SM and Yamamoto M. Optimization of Vector for Pancreatic Cancer Adenoviral Gene Therapy (Am J Surg)
2. Gavrikova T, Davydova JG, Yamamoto-S, Krasnykh V and Yamamoto M. Infectivity enhanced Conditionally Replicative Adenovirus for Hormone-Refractory Prostate Cancer. (J-Urol)
3. Gavrikova T, Davydova JG, and Yamamoto M. The effect of fiber modification onto replicative adenovirus therapeutic function. (J-Virol)
Top of page
PATENTS:
Single-chain Antibody against Hepatitis B Virus Core Protein, Gene Thereof, and Therapeutic Agent for Hepatitis B Containing These Technical Field
International (countries involved in Patent Cooperation Treaty) (pending)
Masato Yamaoto, Norio Hayashi, Hiroko Yamamoto, Naoki Toudo, Sumitomo Pharmasutical Co. Ltd.
Sep 2. 1998
Japanese Domestic (pending)
Masato Yamamoto, Norio Hayashi, Sumitomo Pharmasutical Co. Ltd.
Sep. 2, 1997
Top of page
ORAL PRESENTATIONS:
NCI SPORE Workshop
12TH SPORE Investigators' Workshop, July 10-13, 2004, Baltimore, PRENARY
Concurrent Plenary Session IV: Therapy and Chemoprevention
Davydova J., Gavrikova T, Ono HA, Ramirez PJ, Le LP, Curiel DT, Vickers SM, and Yamamoto M. New Generation Conditionally replicative Adenovirus for Gastrointestinal Cancers
American Association for Cancer Research
96th Annual Meeting, April 16-20, 2005, Anaheim, (Mini Symposium)
Hidetaka A. Ono, Long P. Le, Julia G. Davydova, Tatyana Gavrikova, Pedro J. Ramirez, David T. Curiel, and Masato Yamamoto. Non-invasive in vivo Visualization of Adenovirus Replication with Fluorescent Protein Gene Placed in E3 Region.
Cold Spring Harbor Laboratory Meetings
Target Definition & Vector Design for Molecular Medicine, Nov 10-13, 2005, ORAL and Session Chair. Davydova J, Ono HA, Le L, Curiel DT, Yamamoto M. Non-invasive in vivo Visualization of Adenovirus Replicaiton and its application for Monitoring and Tumor Detection.
Vector Targeting for Gene Therapy, March 20-23, 2003, ORAL and Session Chair.
Davydova J, Le L, Gavrikova T, Ono HA, Ramirez PJ, Krasnykh V, Short J, Wang M, Curiel DT, Yamamoto M. Transcriptionally and Transductionally Targeted Conditionally replicating agents for Esophageal Adenocarcinoma
Vector Targeting for Gene Therapy, March 20-23, 2003, ORAL.
Le P. L, Dmitriev I, Davydova J, Yamamoto M, Curiel DT. Fluorescently Labeled Adenovirus with IX-EGFP for Virus Detection.
Vector Targeting Strategies for Therapeutic Gene Delivery, March 15-18, 2001, ORAL.
Masato Yamamoto, Ramon Alemany, Yasuo Adachi, William E. Grizzle and David T. Curiel.
Characterization of the Cyclooxygenase-2 Promoter in an Adenoviral Vector and Its Application for the Mitigation of Toxicity in Suicide Gene Therapy of Gastrointestinal Caners
Digestive Disease Week (The American Gastroenterological Association)
Digestive Disease Week (DDW) at Anaheim, May 14-19, 2005 (ORAL)
Pedro J. Ramirez, Julia Davydova, Selwyn M. Vickers, David T. Curiel, Masato Yamamoto.
Intravenous Administration of Infectivity Enhanced Conditionally Replicative Adenovirus Shows Augmented Antitumor Effect in Orthotopic Pancreatic Cancer Model
Digestive Disease Week (DDW) at New Orleans, May 16-19, 2004 (ORAL).
Julia Davydova, Long P. Le, Tatyana Gavrikova, Hidetaka Ono, Pedro J. Ramirez, Victor Krasnykh, Minghui Wang, David T. Curiel, Masato Yamamoto. New Generation Conditionally Replicative Adenovirus for Esophageal Adenocarcinima
Digestive Disease Week (DDW) at Atlanta , May 19-22, 2001, ORAL.
Masato Yamamoto, Ramon Alemany, Yasuo Adachi, Willium E Grizzle, David T Curiel.
Cyclooxygenase-2 Promoter Can Mitigate the Lethal Toxicity in HSV-TK Based Adenoviral Suicide Gene Therapy of Gastrointestinal Cancers
Digestive Disease Week (DDW) at Atlanta , May 19-22, 2001, ORAL.
John G Wesseling, Masato Yamamoto, Piter J Bosma, Victor Krasnykh, Jerry L Blackwell, Salwyn M Vickers, Igor Dmitriev, David T Curiel. High Efficiency Gene Transfer to Pancreatic Cancer Cells Using Epidermal Growth Factor Receptor and Integrin Targeted Adenoviral Vectors.
Digestive Disease Week (DDW) at San Diego, May 21-24, 2000, ORAL.
Masato Yamamoto, Ramon Alemany, Yasuo Adachi, Kaori Suzuki and David T. Curiel.
In vivo "LIVER OFF" "TUMOR ON" Gene Expression toward the Gene Therapy of Colon Cancer Liver Metastasis Using Adenovirus Vector with Cyclooxygenase-2 Promoter.
American Society of Gene Therapy
6th annual meeting at Boston, June 4-8, 2003, ORAL
Long P. Le,David A. Matthews, Julia G. Davydova, Masato Yamamoto, David T. Curiel. Core-Labeled Fluorescent Adenovirus for Viral Detection.
6th annual meeting at Boston, June 4-8, 2003, ORAL
New Adenoviral Vectors for Molecular Chemotherapy of Prostate Cancer.
Debbie L. Della Manna, Masato Yamamoto, Victor Krasnykh, Kurt R. Zinn, Julia Davydova, Scott Chiz, Donald J. Buchsbaum.
5th annual meeting at Boston, June 5-9, 2002, ORAL
Yamamoto M, Davydova J, Suzuki K, Nagi AP, Le PL, Krasnykh V, Vickers SM and Curiel DT. Cyclooxygenase-2 (COX-2) Promoter-Based Infectivity Enhanced Conditionally Replicative Adenovirus for COX-2 Positive Gastrointestinal Cancers .
4th annual meeting at Seattle, May 30-June 3, 2001, ORAL
Masato Yamamoto, Ramon Alemany, Yasuo Adachi, William E. Grizzle and David T. Curiel. The Cyclooxygenase-2 Promoter Confers Mitigation of the Lethal Toxicity without Hampering the Efficacy in Adenoviral Suicidal Gene Therapy of Gastrointestinal Cancers.
3rd annual meeting at Denver, May 31-June 4, 2000, ORAL
Yasuo Adachi, Paul Reynolds, Masato Yamamoto and David T. Curiel. Midkine Promoter Based-Adenoviral Gene Therapy for Malignant Tumors.
1st annual meeting at Seattle, May 28-31, 1998, ORAL
Masato Yamamoto, Tetsuo Takehara, Tomohide Tatsumi, Keiji Ueda, Norio Hayshi and Masatsugu Hori. Single-Chain Antibody against Hepatitis B Virus Core Antigen Inhibited Hepatitis B Virus replication in the cells.
Japanese Society of Gene Therapy
The 11th annual meeting at Tokyo, July 28-30, 2005, ORAL
Development of Conditionally Replicative Adenoviruses with Imaging Capability.
Julia G. Davydova, Hidetaka A. Ono, Long P. Le, Seiji Yamamoto, Masato Yamamoto
The 9th annual meeting at Tokyo, July 18-20, 2003, ORAL
Julia Davydova, Tatyana Gavrikova, David T. Curiel and Masato Yamamoto. Transcriptionally and Transductionally Targeted Conditionally Replicating Adenovirus for Gastrointestinal Cancers
Molecular Biology Society of Japan
The 26th annual meeting at Kobe, December 11, 2003, Invited Symposist
Masato Yamamoto. Symposium: Virology and Its Gene Therapy Application: “Next Generation CRAd for GI cancer Gene Therapy”, The Molecular Biology Society of Japan, Kobe Japan.
International Conference on Gene Therapy of Cancer
The 13th annual meeting at San Diego, September 8-10, 2005, Invited ORAL
Julia Davydova, Hidetaka A. Ono, Long P. Le, David T. Curiel, and Masato Yamamoto. Non-invasive in vivo Visualization of Adenoviral Replication and its Application for Monitoring and Tumor Detection.
The 9th annual meeting at San Diego, December 7-9, 2000, Invited ORAL
Masato Yamamoto, Yasuo Adachi, William E. Grizzle and David T. Curiel. Characterization of the Cyclooxygenase-2 Promoter in an Adenoviral Vector and Its Application for the Mitigation of Toxicity in Suicide Gene Therapy of Gastrointestinal Cancers
United European Gastroenterology Week
The 9th United European Gastroenterology Week (UEGW) at Amsterdam, 2001, ORAL
Masato Yamamoto, Ramon Alemany, Yasuo Adachi, Willium E Grizzle, David T Curiel.
Characterization of the Cyclooxygenase-2 Promoter in an Adenoviral Vector and Its Application for the Mitigation of Toxicity in Suicide Gene Therapy of Gastrointestinal Cancers
American Association for the Study of the Liver Diseases
45th annual meeting at Chicago, 1994, ORAL
Masato Yamamoto, Norio Hayashi, Yasuhide Miyamoto, Tetsuo Takehara, Akinori Kasahara, Hideyuki Fusamoto and Takenobu Kamada. In vivo Transfection of the Hepatitis C Virus cDNA to the Adult Rat Liver with Asialoglycoprotein Receptor Mediated Gene Delivery
Top of page
PRESENTATIONS IN JAPANESE:
Only major oral presentations are listed. There are 10-15 more presentations in early trainee days but the records can not be found.
Apr. 1993 Japanese Society of Clinical Metabolism, Oral. Gene Therapy Approach for the Liver Disease Using Asialoglycoprotein Receptor Mediated Gene Delivery
May. 1993 Annual Meeting of Japanese Society of Hepatology, Oral. The Analysis of Hepatitis C Virus Core Antigen cDNA Expression Using Liver Specific Gene Delivery via Asialoglycoprotein Receptor.
Apr. 1994 Annual Meeting of Japanese Society of Hepatology, Oral. In Vivo Liver Specific Gene Delivery of Hepatitis C Virus Core Antigen Using Asialoglycoprotein Receptor Mediated Gene Delivery –chloroquin enhances the gene delivery efficiency in vitro and in vivo-
Sep. 1995 Japanese Society of Gastroenterology, Kinki Divisional Meeting, Symposium “Molecular Biological Approaches for Geatrointestinal Diseases”. Gene Therapy Approach for the Liver Disease Using Asialoglycoprotein Receptor Mediated Gene Delivery
May 1998 Annual Meeting of Japanese Society of Hepatology, Oral. Single-Chain Antibody against Hepatitis B Virus Core Antigen Inhibited Hepatitis B Virus replication in the cells
Top of page
Return to: Medical School : Academic Health Center : myU : U of M Home
